Coupling reactions exploiting the C5 bromine of 5-bromo-3-methylisothiazole proceed via oxidative addition to Pd(0) catalysts. The electron-deficient isothiazole ring accelerates this step relative to electron-rich heteroaryl bromides, reducing induction periods observed in flow calorimetry. A standard Suzuki – Miyaura protocol charges 5-bromo-3-methylisothiazole (1.0 eq), arylboronic acid (1.15–1.3 eq), Pd(PPh₃)₄ (0.01–0.03 eq), and aqueous Na₂CO₃ (2.5 eq) in a toluene/ethanol/water mixture (3:1:1 v/v) at 82 °C for 6–8 h. The biphasic medium allows direct product precipitation upon cooling; a 5-aryl-3-methylisothiazole crystallises with >98 % HPLC purity following recrystallisation from heptane/ethyl acetate. Switching to heteroaryl boronic esters demands ligand tuning: XPhos Pd G2 (0.02 eq) with K₃PO₄ in THF at 65 °C suppresses protodebromination and maintains isolated yields above 87 %. Resultant 5-pyridyl or 5-pyrimidinyl isothiazoles serve as hinge-binding motifs in ATP-competitive kinase inhibitors. In a published route a 5-(2-aminopyrimidin-5-yl)-3-methylisothiazole intermediate was elaborated to a JAK2 inhibitor candidate via amidation and subsequent Buchwald‑Hartwig C‑N coupling with a tailored aminopiperidine. Process-scale execution in 2000 L glass-lined reactors requires controlled boronic acid addition to keep ΔTᵣ below 35 °C as measured by RC1 reaction calorimetry. Residual palladium is reduced to <10 ppm through treatment with trimercaptotriazine-functionalised silica scavengers, meeting ICH Q3D limits for oral solid-dose forms. All batches produced for pharmaceutical filings comply with ICH Q7 Good Manufacturing Practice for active pharmaceutical ingredients; analytical release relies on USP ⟨621⟩ for chromatographic purity and USP ⟨233⟩ for elemental impurities. The terminal drug candidates target inflammatory conditions, where the 3-methylisothiazole core improves metabolic stability and attenuates CYP2C9 inhibition relative to unsubstituted thiazole isosteres.
Is Lithium–Halogen Exchange Tolerated with the Azomethine-Type Isothiazole Moiety?
The C5 bromine of 5-bromo-3-methylisothiazole undergoes clean metal–halogen exchange with n‑butyllithium at −78 °C in anhydrous THF, provided the C3 methyl remains intact. Quenching the lithiated intermediate with 3.0 eq of N,N‑dimethylformamide yields 3-methylisothiazole‑5‑carbaldehyde, a pivot for agrochemical discovery. In a pilot procedure scaled to 10 kg, a suspension of the bromide in THF was cooled below −75 °C before dropwise addition of n‑BuLi (1.05 eq, 2.5 M in hexanes) over 45 min while holding the internal temperature under −70 °C. After a 30‑min hold DMF was introduced, and the mixture was warmed to 0 °C. Fractional vacuum distillation (<1 mbar, head temperature 92–95 °C) delivered the aldehyde in 81–84 % isolated yield. The aldehyde was immediately consumed in a Wittig reaction with benzyltriphenylphosphonium chloride and potassium tert‑butoxide to generate a styryl‑isothiazole, which upon hydrogenation gave a 5-(2-phenylethyl)-3-methylisothiazole derivative bearing a saturated side chain. This motif features in a candidate ryanodine receptor modulator under evaluation for lepidopteran pest control. Compliance with Directive 2009/128/EC on sustainable pesticide use is addressed by scrubbing butane off‑gas and aqueous quench streams to prevent volatile organic discharge. Intermediate quality is enforced by GC‑FID purity >97 % and Karl Fischer water content ≤0.2 %. Process safety studies aligned with the Yoshida correlation confirm that the lithium–halogen exchange remains below thermal-runaway trigger thresholds when the addition rate is capped at 0.15 L min⁻¹ per kilogram of substrate. The terminal agrochemical active ingredients are formulated as suspension concentrates or water-dispersible granules carrying 100–250 g a.i. L⁻¹.
| Coupling Type | Catalytic System | Base/Solvent | Temperature | Isolated Yield Range | End Application of Product |
|---|---|---|---|---|---|
| Suzuki–Miyaura | Pd(PPh₃)₄ 0.02 eq | Na₂CO₃, toluene/EtOH/H₂O | 82 °C | 85–94 % | Kinase inhibitor building blocks |
| Buchwald‑Hartwig Amination | Pd₂(dba)₃ / XPhos 0.04 eq | NaOtBu, toluene | 100 °C | 78–88 % | Diamine-derived agrochemical leads |
| Sonogashira Coupling | Pd(PPh₃)₂Cl₂ 0.03 eq, CuI 0.06 eq | Et₃N, DMF | 70 °C | 90–96 % | Acetylenic pharmacophores |
| Li–Halogen Exchange | n‑BuLi 1.05 eq | — | −78 °C | 81–84 % | 5‑Formyl-3-methylisothiazole for Wittig homologation |
Performance-Based Preservative Concentration Thresholds under EN 15458 versus Real-Time In-Can Challenge Tests
5-Bromo-3-methylisothiazole functions as the upstream intermediate for 2-substituted-3-methylisothiazol-3-one analogues obtained through sequential nucleophilic displacement at C5 and peracetic acid oxidation. A 2-(n‑butyl)-3-methylisothiazol-3-one (BMIT) active, derived in this manner, displays rapid kill kinetics against Pseudomonas aeruginosa and Enterobacter cloacae at levels as low as 15 ppm active ingredient in a high‑pH styrene‑acrylic latex. Blending BMIT with benzisothiazolinone (BIT) at a 1:2 ratio creates a broad-spectrum preservative that is post‑added to waterborne architectural coatings at a total active content of 0.08–0.15 wt% of wet paint, introduced after pigment grind but before let‑down. The addition temperature must stay under 40 °C to avoid thermal ring-opening of the thiazolone. Microbial challenge testing follows EN 15458:2014 Category 2 film preservatives, with a 6‑week cyclical inoculation using a mixed bacterial consortium (Pseudomonas fluorescens, Alcaligenes faecalis, Bacillus subtilis) and fungal strains (Aspergillus niger, Penicillium funiculosum). Coatings formulated with 0.12 wt% total active maintain <100 CFU g⁻¹ through three contamination cycles, satisfying zero‑tolerance regrowth criteria. The cured coating film also meets ISO 11930:2012 preservation benchmarks, enabling brand extension into cosmetic packaging coatings. Regulatory compliance within the European Economic Area demands that the intermediate supplier is registered under the Biocidal Products Regulation (EU) 528/2012; the downstream preservative must appear on the Article 95 list before the formulated product can be placed on the market. In the United States, analogous registration under FIFRA (40 CFR § 152) governs the end‑use biocide. Manufacturing quality of the brominated intermediate is certified by ion‑chromatography HPLC (LOD 0.05 %) and free‑bromide content below 0.1 % w/w to avoid discolouration of light‑tinted paint films.
If Fluid End‑of‑Life Odour Originates from Sulphate‑Reducing Bacteria, Dose‑Response Curves Demand a Rapidly Hydrolysing Reservoir Agent
Central metalworking fluid systems recirculating 20 000 L of a 5 % semi‑synthetic emulsion are vulnerable to colonisation by Desulfovibrio vulgaris, generating hydrogen sulphide that corrodes tungsten carbide tooling. A 5-bromo-3-methylisothiazole‑derived N‑methyl‑isothiazolone pro‑biocide — prepared by quaternisation with dimethyl sulphate followed by controlled hydrolysis — liberates the active free isothiazolone in the alkaline pH 9.2–9.5 typical of boron‑free fluids. Release follows first‑order kinetics with a half‑life of approximately 14 h at 35 °C, circumventing instantaneous depletion by nucleophilic thiolates. A weekly maintenance dose of 80 ppm active equivalent keeps headspace H₂S below 1 ppm for four weeks. Monitoring relies on ATP bioluminescence per ASTM E4012‑22 with an action threshold of 300 RLU mL⁻¹, above which a shock dose of 200 ppm is injected via a proportional dosing pump. The brominated intermediate must be stored as a 20 % concentrate in propylene glycol and kept separate from amines and mercaptobenzothiazole corrosion inhibitors to prevent exothermic decomposition. Compatibility testing according to ASTM D3941‑24 is mandatory to confirm emulsion stability when the concentrate is added to the sump. The formulated biocide is registered under EU BPR product‑type 13 (metal‑working fluid preservative). The concentrate carries classification H301 (toxic if swallowed) and H314 (causes severe skin burns) under CLP Regulation (EC) 1272/2008, mandating butyl rubber gloves and full‑face shields for operators. Spent fluid is treated with hydrogen peroxide/UV oxidative decontamination to reduce active residue below 0.05 mg L⁻¹ before discharge, aligning with OECD industrial wastewater permits.
| End‑Use Segment | Microbiological Standard | Challenge Organisms | Required Criterion | Typical Active Derived | Addition Level (w/w) |
|---|---|---|---|---|---|
| In‑can paint preservation | EN 15458:2014 | P. aeruginosa, E. cloacae, A. niger | <100 CFU g⁻¹ after 3 cycles | 2‑(n‑butyl)-3-methylisothiazol-3-one | 0.08–0.15 % |
| Metalworking fluid | ASTM E4012‑22 | D. vulgaris, P. fluorescens | H₂S <1 ppm, ATP <300 RLU | N‑methyl‑isothiazolone pro‑biocide | 80–200 ppm |
| Flexible PVC | ISO 846:2019 Method A | A. niger, P. pinophilum, C. globosum | Rating 0 (no growth) at 28 d | Thiazolone powder (mp 134–136 °C) | 0.55–0.75 phr |
| Antifouling coating | ASTM D6990‑20 | Ulva zoospores, Balanus cyprids | <5 % coverage after 12‑month immersion | 2‑(4‑chlorobenzyl)-3-methylisothiazol-3-one | 2.5–4.0 % dry film |
Compounding a 5-bromo-3-methylisothiazole‑derived thiazolone biocide into flexible PVC requires pre‑dispersion of the active powder in a plasticiser to eliminate airborne dust and prevent concentration gradients. A masterbatch is prepared by mixing 12 wt% of the benzothiazole‑free thiazolone (melting point 134–136 °C) with diisononyl phthalate in a heated high‑speed mixer at 60 °C until a homogeneous suspension forms. This suspension is metered into a co‑rotating twin‑screw extruder with an L/D ratio of 44:1 and a screw profile containing three kneading blocks that ensure distributive mixing. The PVC compound — consisting of suspension‑grade PVC resin (K‑value 67), DINP (45 phr), epoxidised soybean oil (3 phr, secondary stabiliser), and calcium‑zinc stabiliser (2.5 phr) — receives the biocide suspension to achieve a final active loading of 0.55–0.75 phr. Barrel temperature is profiled at 155/160/165/170/170/165 °C from feed to die; differential scanning calorimetry at 10 K min⁻¹ shows the thiazolone suffers 3 % weight loss only above 198 °C, providing an adequate processing window. Injection moulding into electrical conduit fittings uses a clamping force of 1100 kN and a melt temperature of 185 °C. Finished articles are tested according to ISO 846:2019 Method A with a five‑fungus panel: Aspergillus niger, Penicillium pinophilum, Chaetomium globosum, Gliocladium virens, and Aureobasidium pullulans. An addition level of 0.65 phr achieves a Rating 0 (no growth at 50× magnification) after 28‑day incubation at 29 °C and >95 % RH. Migration into aqueous food simulants is not permitted, restricting the compound to industrial flooring, vapour‑barrier membranes, and non‑food‑contact conduit. Compliance with the RoHS Directive 2011/65/EU Annex II is verified via X‑ray fluorescence screening; the biocide intermediate holds a REACH registration for the 1–10 t a⁻¹ tonnage band. Stearate‑lubricated formulations are antagonistic: the active migrates to the surface within 48 h of extrusion, generating visible bloom; replacing calcium stearate with ethylene bis‑stearamide wax at ≤0.3 phr preserves both aesthetics and fungistatic performance.
